Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 22

Trial Status

Completed3

Role Distribution

Principal Investigator1
Other Roles2
PI Rate33%

Activity Timeline

Research Network

Collaboration Network

12 collaborators·32 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mojca Jongen-Lavrencic, MD

Erasmus Medical Center

Moderately Similar
1 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteMyelodysplastic Syndromes+1 more

Worked with same sponsors:

CelgeneEpizyme, Inc.
Collaborated on 1 trial
Similarity Score44%

David A Rizzieri, MD

Duke University

Moderately Similar
6 trials

Shared therapeutic areas:

Myelodysplastic SyndromesPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute+1 more

Worked with same sponsors:

CelgeneEpizyme, Inc.
Collaborated on 1 trial
Similarity Score44%

Raoul Tibes, MD

Mayo Clinic Scottsdale-Phoenix

Moderately Similar
1 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteMyelodysplastic Syndromes+1 more

Worked with same sponsors:

CelgeneEpizyme, Inc.
Collaborated on 1 trial
Similarity Score44%

Hartmut Döhner, MD

Universitätsklinikum Ulm

Moderately Similar
1 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteMyelodysplastic Syndromes+1 more

Worked with same sponsors:

CelgeneEpizyme, Inc.
Collaborated on 1 trial
Similarity Score44%

Martin S. Tallman, MD

Memorial Sloan Kettering Cancer Center

Moderately Similar
1 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteMyelodysplastic Syndromes+1 more

Worked with same sponsors:

CelgeneEpizyme, Inc.
Collaborated on 1 trial
Similarity Score44%

Jessica Altman, MD

Northwestern University

Moderately Similar
3 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes+1 more

Worked with same sponsors:

CelgeneEpizyme, Inc.
Collaborated on 1 trial
Similarity Score44%

Guillermo Garcia-Manero, MD

M.D. Anderson Cancer Center

Moderately Similar
18 trials

Shared therapeutic areas:

Myelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma+1 more

Worked with same sponsors:

Bristol-Myers SquibbCelgene+1 more
Collaborated on 1 trial
Similarity Score44%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Moderately Similar
24 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma+2 more
Similarity Score30%

Richard W Childs, M.D.

National Heart, Lung, and Blood Institute (NHLBI)

Moderately Similar
15 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteMultiple Myeloma+2 more
Similarity Score30%

Yves Beguin, MD, PhD

CHU-ULg

Moderately Similar
7 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteMultiple Myeloma+2 more
Similarity Score30%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT02843074Phase 2StudyChair

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Multiple Myeloma
Completed
NCT01496118Phase 1/2StudyChair

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma
Completed
NCT01684150Phase 1PrincipalInvestigator

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+1 more
Completed

All 3 trials loaded